Plasma p-tau217 Assays Show High Specificity for Alzheimer’s Diagnosis

The Shift Toward Blood-Based Diagnostics in Alzheimer’s Care

The clinical management of Alzheimer’s disease is undergoing a transition from symptom-based diagnosis to a biological framework defined by in vivo biomarkers [1]. While amyloid-positron emission tomography and cerebrospinal fluid analysis remain the gold standards for detecting pathology, their high cost and invasive nature limit routine use in busy clinical practices [2, 3]. Plasma phosphorylated tau 217 (p-tau217) has emerged as a particularly robust blood-based marker, showing high concordance with brain amyloid deposition and the ability to track disease progression in both preclinical and symptomatic stages [4, 5]. With the recent regulatory approval of amyloid-targeting monoclonal antibodies, the need for accessible, high-performance assays to identify eligible patients has become a clinical priority [6, 7]. A new study now evaluates the diagnostic performance of several emerging assay technologies to determine if they can meet the rigorous demands of differential diagnosis in the clinic.

Comparative Evaluation of Three Assay Technologies

To address the clinical need for accessible Alzheimer’s diagnostics, the study evaluated the diagnostic and differential performance of plasma p-tau217 levels measured with three assays in a Chinese population of 233 participants. This cohort included 39 cognitively unimpaired controls, 28 individuals with mild cognitive impairment due to Alzheimer’s disease, 57 patients with Alzheimer’s disease dementia, 70 individuals with subcortical ischemic vascular dementia, and 39 patients with frontotemporal lobar degeneration. The researchers sought to determine if these emerging technical platforms could reliably distinguish Alzheimer’s pathology from other common causes of cognitive decline, such as vascular or frontotemporal neurodegeneration, which often present with overlapping clinical symptoms. The investigation utilized three distinct technical approaches to quantify the threonine 217 phosphorylated tau protein. The first was an assay based on single-molecule techniques (DiSMS), which utilizes high-sensitivity detection to identify low-abundance proteins in the blood that are otherwise difficult to measure. The second platform utilized a digital enzyme-linked immunosorbent assay (LyMedivh™ AXL), a method that traps individual immunocomplexes in microscopic wells to allow for the precise counting of single molecules. The third approach was an assay based on flow cytometry (CBA), a technique that uses fluorescently labeled beads and laser-based detection to quantify protein concentrations. To ensure the accuracy of these methods, the researchers compared them against a reference assay, the ALZpath Simoa, which is currently an established standard in the field of blood-based biomarker research. The results indicated that all three platforms provided highly accurate measurements of the p-tau217 biomarker. Measurements of the three novel assays demonstrated significant correlations with the ALZpath Simoa measurements (p < 0.01), suggesting that these diverse technical frameworks are consistent with existing high-performance standards. Furthermore, the study found that plasma p-tau217 levels measured with all three assays were significantly higher in the Alzheimer’s disease dementia group than in the cognitively unimpaired control, subcortical ischemic vascular dementia, and frontotemporal lobar degeneration groups (all p < 0.05). When applying optimal cutoff values, the DiSMS and LyMedivh™ AXL assays achieved a specificity of 100% and a sensitivity of 94.4%, while the CBA assay demonstrated a specificity of 100% and a sensitivity of 88.9%.

Study Population and Differential Diagnostic Challenges

The researchers recruited a total of 233 participants to evaluate the diagnostic utility of plasma p-tau217 across a spectrum of cognitive states and etiologies. This cohort was specifically designed to reflect the diagnostic challenges clinicians face in memory clinics, where Alzheimer’s disease must be distinguished from other neurodegenerative and vascular conditions. To establish a baseline for p-tau217 levels in healthy aging, the study included 39 cognitively unimpaired controls (CUCs). To capture the early stages of the disease, the researchers also enrolled 28 individuals with mild cognitive impairment (MCI) due to Alzheimer’s disease, a clinical state where patients exhibit objective cognitive decline but maintain functional independence. Distinguishing Alzheimer’s disease dementia (ADD) from other forms of cognitive impairment is critical for prognosis and treatment planning. The study included 57 individuals with Alzheimer’s disease dementia (ADD) and compared them against two common clinical mimics: subcortical ischemic vascular dementia (SIVD) and frontotemporal lobar degeneration (FTLD). The inclusion of 70 individuals with subcortical ischemic vascular dementia (SIVD), a condition characterized by small vessel disease and white matter changes, and 39 individuals with frontotemporal lobar degeneration (FTLD), which often presents with behavioral or language deficits, allowed the researchers to test the specificity of p-tau217. The ability to differentiate these pathologies is essential because while clinical symptoms often overlap, the underlying proteinopathies require distinct management strategies. For example, identifying an Alzheimer's profile in a patient with mixed vascular features may significantly alter the decision to pursue amyloid-clearing therapies.

High Specificity in Differentiating Dementia Subtypes

The study demonstrated that plasma p-tau217 levels, measured across all three assay platforms, were significantly elevated in patients with Alzheimer’s disease dementia (ADD) compared to cognitively unimpaired controls (CUCs), individuals with subcortical ischemic vascular dementia (SIVD), and those with frontotemporal lobar degeneration (FTLD). Specifically, plasma p-tau217 levels in the ADD group were higher than in the CUC, SIVD, and FTLD groups (all p < 0.05). This elevation allowed the assays to effectively discriminate patients with Alzheimer’s disease dementia from both healthy controls and those with non-Alzheimer’s dementia pathologies. For the clinician, this suggests that p-tau217 can serve as a reliable indicator to rule out common mimics like vascular or frontotemporal dementias, which often present with overlapping cognitive symptoms but require different therapeutic interventions. When evaluating the diagnostic accuracy of these tools using optimal cutoff values (the threshold that maximizes the balance between true positives and true negatives), the researchers found that all three methods achieved a specificity of 100% in differentiating Alzheimer’s disease dementia from other conditions. The single-molecule technique (DiSMS) and the digital enzyme-linked immunosorbent assay (LyMedivh™ AXL) both yielded a sensitivity of 94.4%, while the flow cytometry-based assay (CBA) showed a sensitivity of 88.9%. Despite these slight variations in sensitivity, the diagnostic and differential performances did not significantly differ among the three assays (all p > 0.05). These findings indicate that regardless of the underlying technology used, these p-tau217 assays provide a highly specific means of confirming an Alzheimer’s diagnosis, reducing the risk of false positives in a clinical setting.

Early Detection and Clinical Implications

The clinical utility of p-tau217 extends beyond the stage of overt dementia into the prodromal phase of the disease, where therapeutic intervention may be most effective. In this study, researchers examined a subset of 28 individuals with mild cognitive impairment (MCI) due to Alzheimer’s disease and compared them to 39 cognitively unimpaired controls (CUCs). The data showed that both the single-molecule technique (DiSMS) and the digital enzyme-linked immunosorbent assay (LyMedivh™ AXL) revealed elevated plasma p-tau217 levels in the MCI group compared to the CUC group. This capacity to detect biochemical changes during the mild cognitive impairment stage suggests that these assays can identify Alzheimer’s pathology before significant functional decline occurs, providing clinicians with a wider window for diagnostic confirmation and treatment planning. The findings indicate that these diverse assay platforms offer scalable alternatives to current gold-standard testing methods like positron emission tomography or cerebrospinal fluid analysis. Because the measurements from all three assays demonstrated significant correlations with the ALZpath Simoa reference measurements (p < 0.01), clinicians can have confidence in the reliability of these tools across different laboratory infrastructures. The availability of multiple high-performing platforms, including flow cytometry-based methods, may increase patient access to accurate Alzheimer’s diagnosis in various clinical settings. By providing a highly specific means of confirming Alzheimer’s pathology, these technologies facilitate a more precise diagnostic process, ensuring that patients are correctly identified while those with vascular or frontotemporal pathologies are appropriately triaged for alternative management strategies.

References

1. Jack CR, Bennett DA, Blennow K, et al. NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer s & Dementia. 2018. doi:10.1016/j.jalz.2018.02.018

2. Suresh S, Maffei L, Bauermeister S, Raymont V. Blood biomarkers for diagnosis and differential diagnosis of Alzheimer's disease in real-world clinical populations: A systematic review.. Journal of Alzheimer's disease : JAD. 2026. doi:10.1177/13872877251408510

3. Antonioni A, Raho EM, Lorenzo FD, Manzoli L, Flacco ME, Koch G. Blood phosphorylated Tau217 distinguishes amyloid-positive from amyloid-negative subjects in the Alzheimer's disease continuum. A systematic review and meta-analysis.. Journal of neurology. 2025. doi:10.1007/s00415-025-12996-3

4. Khalafi M, Dartora WJ, McIntire LBJ, et al. Diagnostic accuracy of phosphorylated tau217 in detecting Alzheimer's disease pathology among cognitively impaired and unimpaired: A systematic review and meta-analysis.. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. doi:10.1002/alz.14458

5. Ashton NJ, Janelidze S, Mattsson N, et al. Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring. Nature Medicine. 2022. doi:10.1038/s41591-022-02074-w

6. Zhang J, Zhang Y, Wang J, Xia Y, Zhang J, Chen L. Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies. Signal Transduction and Targeted Therapy. 2024. doi:10.1038/s41392-024-01911-3

7. González‐Ortiz F, Kac PR, Brum WS, Zetterberg H, Blennow K, Karikari TK. Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications. Molecular Neurodegeneration. 2023. doi:10.1186/s13024-023-00605-8